Insisting on lower prices , federal researchers say , would drive away innovative partners that speed the    process and benefit patients .But with the government doing so much the government , others say that the private sector can not afford to walk away ."The market is so reliant on the knowledge and    that comes out of the government and academic labs , " said Dr. Aaron Kesselheim , director of the Program on Regulation , Therapeutics and Law at Brigham   Women â€™s Hospital in Boston .